Literature DB >> 20616311

Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report.

Simon F De Meyer1, Tobias Schwarz, Hans Deckmyn, Cécile V Denis, Bernhard Nieswandt, Guido Stoll, Karen Vanhoorelbeke, Christoph Kleinschnitz.   

Abstract

OBJECTIVE: To unravel crucial von Willebrand factor (VWF) interactions that are detrimental in stroke development. METHODS AND
RESULTS: VWF(-/-) mice received gene transfer to express mutants of VWF defective either in binding to fibrillar collagen, glycoprotein (GP)Ibα or GPIIb/IIIa, and underwent 60 minutes of transient middle cerebral artery occlusion. In VWF(-/-) mice reconstituted with VWF mutants defective in binding to collagen or GPIbα, protection against stroke was sustained, whereas VWF lacking the GPIIb/IIIa binding site restored full susceptibility similar to normal VWF.
CONCLUSIONS: VWF-collagen and VWF-GPIbα (but not VWF-GPIIb/IIIa) interactions are instrumental in thrombus formation after transient middle cerebral artery occlusion, and their inhibition could be a promising target for stroke treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616311     DOI: 10.1161/ATVBAHA.110.208918

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

Review 1.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

2.  Extracellular chromatin is an important mediator of ischemic stroke in mice.

Authors:  Simon F De Meyer; Georgette L Suidan; Tobias A Fuchs; Marc Monestier; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-24       Impact factor: 8.311

Review 3.  von Willebrand factor: an emerging target in stroke therapy.

Authors:  Simon F De Meyer; Guido Stoll; Denisa D Wagner; Christoph Kleinschnitz
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

Review 4.  Ischaemic stroke: a thrombo-inflammatory disease?

Authors:  Bernhard Nieswandt; Christoph Kleinschnitz; Guido Stoll
Journal:  J Physiol       Date:  2011-07-18       Impact factor: 5.182

5.  Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.

Authors:  Monisha Kumar; Wenjing Cao; Jenny K McDaniel; Huy P Pham; Dheeraj Raju; Kelsey Nawalinski; Suzanne Frangos; David Kung; Eric Zager; Scott E Kasner; Joshua M Levine; X Long Zheng
Journal:  Thromb Haemost       Date:  2017-01-19       Impact factor: 5.249

6.  ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.

Authors:  M M Khan; D G Motto; S R Lentz; A K Chauhan
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

Review 7.  Clot Pathophysiology: Why Is It Clinically Important?

Authors:  Patrick A Brouwer; Waleed Brinjikji; Simon F De Meyer
Journal:  Neuroimaging Clin N Am       Date:  2018-09-15       Impact factor: 2.264

8.  Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.

Authors:  Nirav Dhanesha; Prem Prakash; Prakash Doddapattar; Ira Khanna; Molly J Pollpeter; Manasa K Nayak; Janice M Staber; Anil K Chauhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-21       Impact factor: 8.311

9.  Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.

Authors:  Simon F De Meyer; Alexander S Savchenko; Michael S Haas; Daphne Schatzberg; Michael C Carroll; Alexandra Schiviz; Barbara Dietrich; Hanspeter Rottensteiner; Friedrich Scheiflinger; Denisa D Wagner
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

10.  ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice.

Authors:  Chintan Gandhi; David G Motto; Melissa Jensen; Steven R Lentz; Anil K Chauhan
Journal:  Blood       Date:  2012-09-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.